Vericiguat in heart failure with reduced ejection fraction: hope or solid reality?

Area of Science:

• Cardiology
• Pharmacology

Background:

• Recent advancements in heart failure with reduced ejection fraction (HFrEF) treatment, including ARNIs and SGLT2 inhibitors, have improved patient outcomes.
• Despite these advances, a significant residual risk remains in HFrEF patients.
• Vericiguat, an oral soluble guanylate cyclase (sGC) stimulator, targets the NO-sGC-cGMP pathway to reduce oxidative stress and endothelial dysfunction.

Purpose of the Study:

• To review randomized clinical trials, substudies, and meta-analyses on vericiguat in HFrEF.
• To evaluate the potential role of vericiguat as a fifth pillar in HFrEF treatment.
• To identify existing evidence gaps regarding vericiguat's efficacy and application.

Main Methods:

• Review of randomized clinical trials, substudies, and meta-analyses concerning vericiguat in HFrEF patients.
• Analysis of data from the Victoria trial demonstrating vericiguat's impact on cardiovascular mortality and heart failure hospitalizations.
• Examination of vericiguat's efficacy in patient subgroups, including those with comorbidities like renal failure.

Main Results:

• The Victoria trial showed a 10% reduction in the composite of cardiovascular mortality and heart failure rehospitalization with vericiguat.
• Vericiguat significantly reduced heart failure hospitalizations.
• Vericiguat demonstrated therapeutic value in patients with comorbidities who cannot tolerate standard HFrEF therapies.

Conclusions:

• Vericiguat shows potential as a fifth pillar in HFrEF treatment, offering benefits beyond current therapies.
• Current guidelines recommend vericiguat as a second-line therapy for symptomatic HFrEF patients despite optimized treatment.
• Further research is needed to clarify remaining evidence gaps and fully establish vericiguat's role in HFrEF management.